% | $
Quotes you view appear here for quick access.

NPS Pharmaceuticals, Inc. Message Board

  • dcaf7 dcaf7 Mar 19, 2013 10:33 PM Flag

    Preotact paradox

    NPS is considering to abandon osteoporosis indication in Europe which generated north of $80 million revenue in 2011 to persue an orphan indication, hypoparathyroidism. Is any other example in pharmaceutical industry for a company that stop selling a drug for a major disease in order to switch to an orphan condition?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hi dcaf,
      Don't know the answer to your question but I read that NPS hired Sandy Smith ,former president of Genzymes's international unit, as a commercialization consultant focused on international expansion . So
      sounds like they have a good person leading the charge. Sure is a interesting and exciting move today.
      Good days ahead and good luck to you.

      Sentiment: Strong Buy

45.970.00(0.00%)Feb 20 3:59 PMEST